BAT to Launch Synthetic Nicotine e-Cigarette in South Korea

Sep.23.2024
BAT to Launch Synthetic Nicotine e-Cigarette in South Korea
BAT plans to release a synthetic nicotine e-cigarette named "Nomad" in South Korea, taking advantage of legal loopholes there.

According to N.News on September 23rd, British American Tobacco (BAT) announced that they will be releasing a synthetic nicotine e-cigarette in November.


British American Tobacco's South Korean subsidiary revealed on the 23rd that its synthetic nicotine e-cigarette, named "Nomad", has applied for a trademark and is scheduled to be officially launched in November.


BAT hinted as early as May of this year that it was planning to launch this new product. Currently, South Korea will be the only country in the world to sell this synthetic nicotine e-cigarette.


Industry insiders believe that BAT is interested in South Korea due to the lack of clear legal regulations on synthetic nicotine e-cigarettes in the country. According to current tobacco laws in South Korea, only products made from tobacco leaves are recognized, so synthetic nicotine e-cigarettes are not considered traditional tobacco products. This allows them to be sold online and to minors without restrictions.


In addition, these synthetic nicotine e-cigarettes are not subject to taxation, which means their prices may be lower than regular tobacco and traditional e-cigarettes.


According to reports, discussions regarding legal amendments in South Korea have been stalled. During the 21st National Assembly session, four bills aimed at expanding the definition of tobacco to include synthetic nicotine products were proposed, but were ultimately scrapped as the parliamentary term came to an end. In the 22nd National Assembly, there are currently five related bills proposed.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
FDA PMTA Roundtable: Ongoing Comprehensive Coverage by 2Firsts
Feb.11
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
Elfbar warns flavour bans could push over 50,000 Scottish vapers back to smoking
Elfbar warns flavour bans could push over 50,000 Scottish vapers back to smoking
Elfbar said restricting vape flavour choices—potentially under the Tobacco and Vapes Bill—could disrupt established quitting behaviours and increase relapse risk among former smokers. An Opinium survey commissioned by the company reported fruit and sweet flavours have risen in popularity among adult vapers quitting smoking in Scotland, with 62% now using them most often to quit, up from 34% in December 2024.
Feb.28 by 2FIRSTS.ai
Alabama SB9 advances: Senate committee clears bill to treat vaping like smoking in enclosed public places
Alabama SB9 advances: Senate committee clears bill to treat vaping like smoking in enclosed public places
Alabama’s Senate Bill 9 advanced after clearing the Senate Committee on Healthcare, moving to the full Alabama Senate for consideration. The proposal would update the state’s 2003 Clean Indoor Air Act by including e-cigarettes and other vaping devices under the same restrictions that apply to smoking in most enclosed public places.
Jan.22 by 2FIRSTS.ai
Bulgaria’s Disposable Vape Ban Receives Formal Approval From the European Commission
Bulgaria’s Disposable Vape Ban Receives Formal Approval From the European Commission
The European Commission has formally published its decision approving Bulgarian legislation banning the placing on the market, offering and sale of disposable e-cigarettes.
Mar.17 by 2FIRSTS.ai
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
Special Report|Reynolds’ 337 Patent Case Ends, but a Harsher 337 Compliance Battle Now Targets the Entire Vape Supply Chain
The U.S. International Trade Commission (ITC) has terminated Investigation 337-TA-1410 after invalidating key vape patent claims asserted by R.J. Reynolds Vapor Company, removing the immediate risk of import bans for dozens of companies. However, a new case—337-TA-1486—has already opened a more consequential legal front, shifting the focus from patent disputes to regulatory compliance across the vape supply chain, including PACT Act reporting, tax compliance, and FDA marketing authorization.
BAT
Mar.11